Background
Prospective single-institution study (NCI) followed by a multicenter validation. Dunleavy et al (NEJM 2013, N=30) evaluated dose-adjusted EPOCH-R (DA-EPOCH-R) for newly diagnosed sporadic and immunodeficiency-associated Burkitt lymphoma in adults, avoiding prophylactic cranial irradiation. SC-EPOCH-RR (lower-intensity) was evaluated in HIV-positive patients (N=11). Roschewski et al (JCO 2020, N=98, multicenter) confirmed the results in a larger cohort. Published NEJM 2013 + JCO 2020.
Interventions and follow up
Regimen: DA-EPOCH-R — dose-adjusted etoposide 50 mg/m²/d, vincristine 0.4 mg/m²/d, doxorubicin 10 mg/m²/d CIV × 4d + cyclophosphamide 750 mg/m² IV day 5 + prednisone 60 mg/m² PO BID days 1–5 + rituximab 375 mg/m² day 1, every 21d × 6 cycles, with IT methotrexate
Primary endpoint: Freedom from progression (FFP) and overall survival
mFollow up: 86 months (HIV-neg, NCI cohort); 49 months (multicenter cohort)
Primary endpoint: Freedom from progression (FFP) and overall survival
mFollow up: 86 months (HIV-neg, NCI cohort); 49 months (multicenter cohort)
Results
FFP (HIV-negative, DA-EPOCH-R, NCI cohort): 95% at 86 months
OS (HIV-negative, DA-EPOCH-R, NCI cohort): 100%
FFP (HIV-positive, SC-EPOCH-RR, NCI cohort): 100%
OS (HIV-positive, NCI cohort): 90%
4-year EFS (multicenter, Roschewski JCO 2020, N=98): ~87%; 4-year OS ~89%
CNS relapse rate: 0% without prophylactic intrathecal chemotherapy (in low/intermediate CNS-risk patients)
OS (HIV-negative, DA-EPOCH-R, NCI cohort): 100%
FFP (HIV-positive, SC-EPOCH-RR, NCI cohort): 100%
OS (HIV-positive, NCI cohort): 90%
4-year EFS (multicenter, Roschewski JCO 2020, N=98): ~87%; 4-year OS ~89%
CNS relapse rate: 0% without prophylactic intrathecal chemotherapy (in low/intermediate CNS-risk patients)
Adverse events
Hematologic/infectious: Fever and neutropenia in 22% of cycles; dose adjustments reduced excessive myelosuppression
Metabolic: Tumor lysis syndrome in 1 patient (NCI cohort)
Deaths/other: 0 treatment-related deaths (NCI cohort), 1 (multicenter); HIV-positive patients managed with concurrent ART, infections a concern; no anthracycline cardiomyopathy in short-term follow-up
Metabolic: Tumor lysis syndrome in 1 patient (NCI cohort)
Deaths/other: 0 treatment-related deaths (NCI cohort), 1 (multicenter); HIV-positive patients managed with concurrent ART, infections a concern; no anthracycline cardiomyopathy in short-term follow-up
Conclusions
DA-EPOCH-R achieved ~95% freedom from progression and 100% OS in HIV-negative adult Burkitt lymphoma with a short infusion schedule and no prophylactic intrathecal chemotherapy or cranial radiation. These results, confirmed in 98 patients by Roschewski et al, establish DA-EPOCH-R as a standard of care for adult Burkitt lymphoma in the US, with equivalent or superior outcomes to intensive hyperCVAD-based regimens and substantially less toxicity.
Key Limitations
Single-arm, non-randomized design; no direct head-to-head comparison with hyperCVAD or CODOX-M/IVAC. Small NCI discovery cohort (N=30 HIV-neg; N=11 HIV-pos). Selection bias possible at a referral center. Patients with high CNS risk or overt CNS disease were under-represented, so the omission of intrathecal/cranial prophylaxis may not generalize to high CNS-risk disease. Confirmatory multicenter EFS (~87%) was slightly lower than the discovery cohort. Note: this entry is filed under cat3=ALL though Burkitt lymphoma is a mature B-cell lymphoma/leukemia — classification should be reviewed.
Clinical Context
DA-EPOCH-R is a widely adopted standard for adult sporadic and HIV-associated Burkitt lymphoma, offering a less toxic alternative to CODOX-M/IVAC and hyperCVAD. ESMO and ASCO-aligned practice recognize DA-EPOCH-R particularly in older or comorbid patients and those with HIV. It is not appropriate for high CNS-risk or bulky high-tumor-burden disease, where more intensive CNS-directed regimens are preferred.